Patents by Inventor Thomas W. Leonard

Thomas W. Leonard has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190393816
    Abstract: A motor drive and method of controlling a motor are provided. The motor drive includes a controller generating a motor reference voltage; a DC bus providing a DC voltage having a ripple; an inverter including power switches operable to convert the DC voltage into an AC motor voltage by modulating the power switches during a plurality of switching cycles, the AC motor voltage based on the motor reference voltage; a capacitor circuit coupled to the DC bus and having a maximum capacitance that is less than 10 microfarads per ampere of a rated current; and voltage prediction logic structured to: detect a voltage value corresponding of the ripple during each of the plurality of switching cycles; and modify the motor reference voltage during each of the plurality of switching cycles using the voltage value.
    Type: Application
    Filed: January 29, 2018
    Publication date: December 26, 2019
    Inventors: Vladimir A. Chedygov, Scott E. Leonard, Dalton H. Paull, Andre P. Perra, Thomas W. Trullinger
  • Patent number: 10051715
    Abstract: The present disclosure relates to a system that utilizes Power over Ethernet (PoE) to supply low voltage direct current (DC) power to a PoE enabled track lighting system. The system facilitates communications with individual track heads located in a PoE enabled low voltage track channel so that the operational characteristics of the individual track heads can be controlled (e.g., dim, brighten, change color), so that feedback on functional status of individual track heads can be obtained, and so that total system current can be regulated. The PoE track lighting system includes a PoE track interface (PTI) device that receives current and communication signals. The PTI device receives the digital communication signals, converts them to a second digital commination signal in a format more suitable for transmission along the communication conductors in the track channel, and transmits the second digital communication signal to the communication conductors of the track channel.
    Type: Grant
    Filed: November 8, 2017
    Date of Patent: August 14, 2018
    Assignee: Leviton Manufacturing Co., Inc.
    Inventors: Robert L. Hick, Kenneth Eidsvold, Thomas W. Leonard
  • Publication number: 20180139823
    Abstract: The present disclosure relates to a system that utilizes Power over Ethernet (PoE) to supply low voltage direct current (DC) power to a PoE enabled track lighting system. The system facilitates communications with individual track heads located in a PoE enabled low voltage track channel so that the operational characteristics of the individual track heads can be controlled (e.g., dim, brighten, change color), so that feedback on functional status of individual track heads can be obtained, and so that total system current can be regulated. The PoE track lighting system includes a PoE track interface (PTI) device that receives current and communication signals. The PTI device receives the digital communication signals, converts them to a second digital commination signal in a format more suitable for transmission along the communication conductors in the track channel, and transmits the second digital communication signal to the communication conductors of the track channel.
    Type: Application
    Filed: November 8, 2017
    Publication date: May 17, 2018
    Inventors: Robert L. Hick, Kenneth Eidsvold, Thomas W. Leonard
  • Publication number: 20150238561
    Abstract: The present invention provides compositions of GnRH related compounds that are suitable for oral administration, injectable administration and other forms of administration wherein the gelling characteristics of the composition are a factor. The compositions of the present invention comprise a therapeutically effective amount of one or more GnRH related compound, and a sufficient amount of at least one anti-gelling agents to reduce the gelation of the GnRH related compound. The present invention also provides processes for preparation of a composition of one or more GnRH related compound, wherein the process comprises mixing the GnRH related compound with one or more anti-gelling agents, wherein the anti-gelling agent comprises a medium chain fatty acid salt, or an ester, an ether, or a derivative of a medium chain fatty acid and has a carbon chain length of from about 4 to about 20 carbon atoms or is a surface active agent.
    Type: Application
    Filed: March 3, 2015
    Publication date: August 27, 2015
    Inventors: Amanda Lee, Bozena Adamczyk, David C. Coughlan, Edel O'Toole, Thomas W. Leonard
  • Patent number: 9089484
    Abstract: The present invention provides pharmaceutical compositions for oral administration comprising a therapeutically effective amount of a selective factor Xa inhibitor or a pharmaceutically acceptable salt thereof and an enhancer, wherein the enhancer is a medium chain fatty acid or a salt, ester, ether, or derivative of a medium chain fatty acid and has a carbon chain length of from about 4 to about 20 carbon atoms. The present invention also provides a method for obtaining a reproducible bioavailability of selective factor Xa inhibitor in an object after oral administration comprising orally administering a pharmaceutical composition as described above.
    Type: Grant
    Filed: March 28, 2011
    Date of Patent: July 28, 2015
    Assignee: Merrion Research III Limited
    Inventors: Thomas W. Leonard, David C. Coughlan, Alan Cullen
  • Patent number: 8999383
    Abstract: The present invention provides compositions of GnRH related compounds that are suitable for oral administration, injectable administration and other forms of administration wherein the gelling characteristics of the composition are a factor. The compositions of the present invention comprise a therapeutically effective amount of one or more GnRH related compound, and a sufficient amount of at least one anti-gelling agents to reduce the gelation of the GnRH related compound. The present invention also provides processes for preparation of a composition of one or more GnRH related compound, wherein the process comprises mixing the GnRH related compound with one or more anti-gelling agents, wherein the anti-gelling agent comprises a medium chain fatty acid salt, or an ester, an ether, or a derivative of a medium chain fatty acid and has a carbon chain length of from about 4 to about 20 carbon atoms or is a surface active agent.
    Type: Grant
    Filed: May 7, 2009
    Date of Patent: April 7, 2015
    Assignee: Merrion Research III Limited
    Inventors: Amanda Lee, Bozena Adamczyk, David C. Coughlan, Edel O'Toole, Thomas W. Leonard
  • Publication number: 20140239821
    Abstract: A system has a lighting fixture has a first connector electrically coupled to a power supply, the first connector being separately electrically coupled to a load, an occupancy sensor having a second connector adapted and configured to engage the first connector, the occupancy sensor being capable of detecting a presence of a person within a monitored space, the first and second connectors forming a disconnect for the lighting fixture, and a switch located in the occupancy sensor arranged to electrically couple the power supply and the load when the first connector is coupled to the second connector and when the occupancy sensor detected a person's presence within the monitored space.
    Type: Application
    Filed: February 27, 2013
    Publication date: August 28, 2014
    Applicant: LEVITON MANUFACTURING CO., INC.
    Inventor: Thomas W. Leonard
  • Patent number: 8802114
    Abstract: The present invention generally relates to orally administered pharmaceutical compositions of iron compounds with medium chain fatty acid salts. The invention further relates to methods of using the pharmaceutical compositions to treat iron deficiency and related disorders.
    Type: Grant
    Filed: January 6, 2012
    Date of Patent: August 12, 2014
    Assignee: Merrion Research III Limited
    Inventors: Alan Cullen, Edel O'Toole, David C. Coughlan, Kishore Chalasani, Thomas W. Leonard
  • Patent number: 8710697
    Abstract: An electrical power pack may include a first power switch and a cycle control to cycle between the first power switch and a second power switch. An electrical power pack may include a first power switch and a delay element to delay an operation of the first power switch. A power pack system may include a first power switch to operate in response to a constant-on control and a second power switch to operate in response to an automatic control. A power pack system may include a first power switch to operate in response to a manual-on control, and a second power switch to operate in response to an automatic-on control.
    Type: Grant
    Filed: July 26, 2011
    Date of Patent: April 29, 2014
    Assignee: Leviton Manufacturing Co., Inc.
    Inventors: Thomas W. Leonard, Robert Hick
  • Publication number: 20120296487
    Abstract: An occupancy sensing system includes a vacate input to cause the system to turn lights on without substantial delay when a monitored space becomes occupied after turning the load off in response to the vacate input. A special vacate input may be eliminated by determining, in response to a manual-off input, if the space has been vacated. A dead time may be included to prevent the lights from being turned back on by movement that is detected as occupants vacate the monitored space after pressing a vacate or manual-OFF button.
    Type: Application
    Filed: May 18, 2011
    Publication date: November 22, 2012
    Applicant: LEVITON MANUFACTURING CO., INC.
    Inventors: Richard A. Leinen, Robert L. Hick, Thomas W. Leonard
  • Publication number: 20120189692
    Abstract: The present invention generally relates to orally administered pharmaceutical compositions of iron compounds with medium chain fatty acid salts. The invention further relates to methods of using the pharmaceutical compositions to treat iron deficiency and related disorders.
    Type: Application
    Filed: January 6, 2012
    Publication date: July 26, 2012
    Inventors: Alan Cullen, Edel O'Toole, David C. Coughlan, Kishore Chalasani, Thomas W. Leonard
  • Publication number: 20120156294
    Abstract: The present invention provides pharmaceutical compositions for oral administration comprising a therapeutically effective amount of a selective factor Xa inhibitor or a pharmaceutically acceptable salt thereof and an enhancer, wherein the enhancer is a medium chain fatty acid or a salt, ester, ether, or derivative of a medium chain fatty acid and has a carbon chain length of from 4 to 20 carbon atoms. The present invention also provides a method for obtaining a reproducible bioavailability of selective factor Xa inhibitor in a subject after oral administration comprising orally administering a pharmaceutical composition as described above.
    Type: Application
    Filed: September 23, 2011
    Publication date: June 21, 2012
    Inventors: Thomas W. Leonard, David C. Coughlan, Alan Cullen
  • Patent number: 8076319
    Abstract: The present invention includes methods for preventing endometrial hyperplasia associated with estrogen therapy through the administration of a progestin agent. The methods presented may include starting the administration of a progestin agent at a high dose, and then lowering the dose.
    Type: Grant
    Filed: February 4, 2010
    Date of Patent: December 13, 2011
    Assignee: Barr Laboratories, Inc.
    Inventor: Thomas W. Leonard
  • Publication number: 20110278922
    Abstract: An electrical power pack may include a first power switch and a cycle control to cycle between the first power switch and a second power switch. An electrical power pack may include a first power switch and a delay element to delay an operation of the first power switch. A power pack system may include a first power switch to operate in response to a constant-on control and a second power switch to operate in response to an automatic control. A power pack system may include a first power switch to operate in response to a manual-on control, and a second power switch to operate in response to an automatic-on control.
    Type: Application
    Filed: July 26, 2011
    Publication date: November 17, 2011
    Applicant: LEVITON MANUFACTURING CO., INC.
    Inventors: Thomas W. Leonard, Robert Hick
  • Publication number: 20110236474
    Abstract: The present invention provides pharmaceutical compositions for oral administration comprising a therapeutically effective amount of a selective factor Xa inhibitor or a pharmaceutically acceptable salt thereof and an enhancer, wherein the enhancer is a medium chain fatty acid or a salt, ester, ether, or derivative of a medium chain fatty acid and has a carbon chain length of from about 4 to about 20 carbon atoms. The present invention also provides a method for obtaining a reproducible bioavailability of selective factor Xa inhibitor in an object after oral administration comprising orally administering a pharmaceutical composition as described above.
    Type: Application
    Filed: March 28, 2011
    Publication date: September 29, 2011
    Inventors: Thomas W. Leonard, David C. Coughlan, Allan Cullen
  • Patent number: 8008802
    Abstract: An electrical power pack may include a first power switch and a cycle control to cycle between the first power switch and a second power switch. An electrical power pack may include a first power switch and a delay element to delay an operation of the first power switch. A power pack system may include a first power switch to operate in response to a constant-on control and a second power switch to operate in response to an automatic control. A power pack system may include a first power switch to operate in response to a manual-on control, and a second power switch to operate in response to an automatic-on control.
    Type: Grant
    Filed: March 3, 2009
    Date of Patent: August 30, 2011
    Inventors: Thomas W. Leonard, Robert Hick
  • Publication number: 20110182985
    Abstract: The present invention provides pharmaceutical compositions which are effective in providing therapeutically effective blood levels of a therapeutically active ingredient to a subject when administered to a gastrointestinal tract. In one aspect, the pharmaceutical compositions comprise a therapeutically effective amount of a therapeutically active ingredient; at least one water soluble enhancer, e.g., a medium chain fatty acid or a salt, ester, ether, or derivative of a medium chain fatty acid and has a carbon chain length of from about 4 to about 20 carbon atoms; and a saccharide.
    Type: Application
    Filed: January 26, 2011
    Publication date: July 28, 2011
    Inventors: David C. Coughlan, Thomas W. Leonard, Bozena Adamczyk, Kieran Madigan, Edel O'Toole, Alan Cullen, Jason O'Hara
  • Publication number: 20110090042
    Abstract: A wireless demand response endpoint includes a power switch and a wireless receiver to control the power switch in response to a wireless demand signal. The wireless demand signal may be transmitted at the same premises as the endpoint. One or more wireless endpoints at the premises may be configured to respond to the wireless demand signal. The wireless demand signal may be transmitted automatically, manually, or in other modes. Power switching may be on/off, dimming, etc.
    Type: Application
    Filed: October 21, 2009
    Publication date: April 21, 2011
    Applicant: Leviton Manufacturing Co., Inc.
    Inventors: Thomas W. Leonard, Richard A. Leinen, Robert L. Hick
  • Publication number: 20100247640
    Abstract: The invention relates to a pharmaceutical composition and oral dosage forms comprising a bisphosphonate in combination with an enhancer to enhance intestinal delivery of the bisphosphonate to the underlying circulation. Preferably, the enhancer is a medium chain fatty acid or a medium chain fatty acid derivative having a carbon chain length of from 6 to 20 carbon atoms, and the solid oral dosage form is a controlled release dosage form such as a delayed release dosage form.
    Type: Application
    Filed: April 26, 2010
    Publication date: September 30, 2010
    Inventor: Thomas W. Leonard
  • Patent number: 7800498
    Abstract: The present invention discloses an apparatus and method for converting a low voltage occupancy sensor to a powered stand-alone unit. The invention uses a low voltage occupancy sensor mounted in an upper portion of a housing with its associated low voltage wiring terminating in a terminal block. An attachable corresponding lower housing is provided with a power pack adapted to connect with the low voltage terminal block wherein once combined the upper and lower housing portions combine to form an integral powered stand-alone sensor unit.
    Type: Grant
    Filed: March 28, 2007
    Date of Patent: September 21, 2010
    Assignee: Leviton Manufacturing Co., Inc.
    Inventors: Thomas W. Leonard, Richard A. Leinen, John B. Engel